New cream may soothe painful rashes from cancer drugs
NCT ID NCT06399029
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a cream containing ruxolitinib can improve skin rashes caused by anti-PD1 cancer immunotherapy. About 22 adults with this type of rash will use the cream for 12 weeks. The goal is to see if the rash clears by at least 90%.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXANTHEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University hospital Zürich, Department Dermatology
Zurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.